Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. “Based on these data, we plan to open an expanded trial,” David Reese, Amgen’s head of research and development, said in an interview. “We want to begin exploring quickly enrollment in earlier lines of therapy.”  Amgen’s pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body’s immune system can kill the cancer, are a cornerstone of the biotech company’s oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies’ more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient’s own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the “off the shelf” nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that  worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.
[A]: Amgen antibody shows promise in myeloma trial, gets FDA fast track.


[Q]: Peebles, a 30-year-old black man who’s skeptical of what he hears from the news media and government, initially didn’t see the need for alarm over the virus. “I felt it was a complete hoax,” Peebles said. “This thing happens every two or four years. We have an outbreak of a disease that seems to put everybody in a panic.” Peebles is among roughly 40 million black Americans deciding minute by minute whether to put their faith in government and the medical community during the coronavirus pandemic. Historic failures in government responses to disasters and emergencies, medical abuse, neglect and exploitation have jaded generations of black people into a distrust of public institutions. “I’ve just been conditioned not to trust,” said Peebles, who is now obeying the state’s stay home order and keeping his distance from others when he goes out. Some call such skepticism the “Tuskegee effect” — distrust linked to the U.S. government’s once-secret study of black men in Alabama who were left untreated for syphilis. Black people already suffer disproportionately from chronic conditions like diabetes and heart disease and are far more likely to be uninsured. How the government and medical community responds to the crisis will be especially crucial for outcomes among black Americans, civil rights advocates and medical experts say. “We are right to be paranoid and to ask tough questions,” said U.S. Rep. Ayanna Pressley of Massachusetts who joined other congressional leaders in asking the government to collect and release information about the race and ethnicity of people who are tested or treated for the virus that causes COVID-19. “History has shown us, when we do not” ask questions, said Pressley, who is black, “the consequences are grave, and in fact life and death.”  NAACP President Derrick Johnson, who hosted a coronavirus tele-town hall with U.S. Surgeon General Jerome Adams last month, said black and brown communities need reliable information about the crisis. “Now that this has been deemed a pandemic, I am most concerned with inequities in who’s provided tests, who’s provided treatment and how those tests and the treatments are administered, in a way that is open, transparent, and equitable,” Johnson said. For most people, the virus causes mild or moderate symptoms, such as fever and cough. But for some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia and death. Cities with large black populations like New York, Chicago, Detroit, Milwaukee and New Orleans have emerged as hot spots for the coronavirus. Figures released by Michigan’s Department of Health and Human Services show 40% of those who have died from COVID-19 are black in a state where African-Americans are just 14% of the population. And many Southern states with large black populations have been slow to mandate statewide restrictions shown to slow virus spread. According to the U.S. Department of Health and Human Services, black adults are 60% more likely than non-Hispanic white adults to be diagnosed with diabetes, 40% more likely to have high blood pressure and are less likely to have those conditions under control. Additionally, in 2015, black women were 20% more likely to have asthma than non-Hispanic whites. Those disparities make the availability of a treatment or vaccine urgent, even as the virus is currently projected to claim tens of thousands of lives. But given history, Peebles said he wouldn’t rush to accept a remedy. “If we got to a place where the government says, ‘OK, now it’s time to take a vaccine,’ then I’m definitely going to be skeptical of their intentions,” he said. Launched in 1932 by the U.S. Public Health Service, the Tuskegee study involved roughly 600 poor black men in Alabama who weren’t treated for the sexually transmitted disease so researchers could track its progress. The program was exposed and ended in 1972, and then-President Bill Clinton formally apologized in 1997. The Tuskegee legacy has helped pollute the black community’s relationship with American medical science. A 2016 paper found the fallout included mistrust of medicine among black men, along with fewer interactions with doctors and higher mortality rates. In Tuskegee, where many families include descendants of victims, many residents don’t trust government health information, said Lucenia Dunn, a former Tuskegee mayor. So volunteers trying to get the word out about coronavirus have gone door-to-door distributing fliers with cartoon-like illustrations that don’t look “too official,” she said. “We have a general distrust in this community,’” Dunn said. “I call it ‘subconscious rejection.’ The attitude is, ‘I’m going to rebel against this. You people have been telling us lies for years. Why should I believe you now?’” In Los Angeles, Jahmil Lacey helped found a public health group for black men and boys, TRAPMedicine, that educates black barbers and organizes workshops to address health disparities among their customers. “People will quote the Tuskegee experiment as the reason why black people don’t trust health care, but there’s so much more than just that one example,” Lacey said. “We don’t trust systems that are connected to white supremacy. So, we have to do the work to repair it.” Indeed, Tuskegee didn’t happen in a vacuum. In the 1950s, doctors at the John Hopkins Hospital used cervical cancer cells from Henrietta Lacks, a black mother of five, to pioneer medical advances and research that continue globally today. Lacks, who died in 1951, never gave her consent and her family has never been compensated. One way to begin healing the mistrust is to increase black representation in the medical field, said Dr. Nicollette Louissaint, executive director of the Washington-based emergency response advocacy group Healthcare Ready. “We have to make sure that ... the message itself and the messengers are being adapted to the appropriate audience,” said Louissaint, who is black. “It’s going to be really important that we get that right.” ___ Reeves reported from Birmingham, Alabama. Both are members of the AP’s Race and Ethnicity team. Follow Morrison on Twitter at http://twitter.com/aaronlmorrison. Follow Reeves on Twitter at https://twitter.com/Jay_Reeves
[A]: Amid coronavirus pandemic, black mistrust of medicine looms.


[Q]: A quote from one of the study’s co-authors mentions “costs” and “patient preferences” as sensible considerations in first choice of antidepressant therapy, but the release offers no information about the comparative costs of the drugs that were studied or even the estimated average annual cost of such therapy. The release would have been strengthened by such data. The release states that “After two years, nonsmokers lost an average of 2.4 pounds on bupropion–compared with gaining an average of 4.6 pounds on fluoxetine (Prozac). So those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.” With the exception of a mention that some people can’t take buproprion (seizure disorder patients, for example), and the weight gain issue, the release makes no mention of the considerable side effects that accompany antidepressant use, or the often frustrating search patients and physicians must undertake to find an antidepressant that is both effective and tolerable for individual patients. Fatigue, insomnia, increased anxiety, headache and nausea are all fairly common when starting an antidepressant. The release does not make it clear that this is a retrospective study and not one set up to study the effect of antidepressants on weight gain or loss. The published study’s summary offered detailed information about the makeup of the study population and the strengths and weaknesses of the study’s data and analytic approach. Not much of that information was used in the release. To be helpful to readers, the release should have noted at least some of these limitations that were pointed out in the study: The release doesn’t engage in disease mongering. Nor does it give us any context about the prevalence of depression which might have been warranted here. That’s pretty well covered, with lots of information about Group Health and the grantors. In essence, the purpose of this study was to compare alternatives and report their effect on weight gain or loss. The news release notes that fluoxetine was chosen as the “reference” drug to compare with buproprion. The study suggests that in addition to fluoxetine, the researchers looked at data from patients assigned to a number of other drugs, too, but their data sets were incomplete. The release makes clear that all of the antidepressants are available and approved. The release claims that the study was the first to examine weight gain in people using antidepressants for more than a year, in this case up to two years. The release doesn’t rely on unjustifiable language. We would underscore the study author’s comment that “bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese” by adding that each individual needs to be evaluated for their symptoms with a medical professional making a recommendation on the appropriate drug therapy.
[A]:
One antidepressant shown to control weight during 2-year study